What is the recommended treatment for influenza in the United States?

Treatment for Influenza in the United States

Start antiviral treatment immediately with a neuraminidase inhibitor (oseltamivir, zanamivir, or peramivir) for any patient hospitalized with influenza, those with severe/progressive illness, high-risk patients, children under 2 years, adults ≥65 years, and pregnant/postpartum women—do not wait for test results or worry about illness duration. 1

Who Must Receive Antiviral Treatment

The IDSA guidelines provide clear criteria for mandatory antiviral therapy 1:

Treat immediately regardless of vaccination status or illness duration:

• Any hospitalized patient with suspected or confirmed influenza
• Outpatients with severe or progressive illness at any stage
• High-risk patients including those with chronic medical conditions or immunocompromised states
• Children younger than 2 years
• Adults ≥65 years or older
• Pregnant women and those within 2 weeks postpartum

May consider treatment for:

• Otherwise healthy outpatients not at high risk (though early treatment still reduces symptom duration)

First-Line Antiviral Selection

Use a single neuraminidase inhibitor—never combine multiple antivirals 1:

For uncomplicated influenza (5-day course):

• Oral oseltamivir (most widely used, proven efficacy)
• Inhaled zanamivir (alternative, particularly effective against influenza B)
• Single-dose IV peramivir (when oral/inhaled routes unavailable)

Oseltamivir remains the dominant antiviral in US practice, accounting for over 90% of prescriptions, consistent with its broad FDA approval across age groups and settings 2. Baloxavir, despite WHO's conditional recommendation for high-risk patients 3, has seen limited uptake (1.8-9.2% of prescriptions) since 2018 approval 2.

Dosing and Duration

Standard treatment:

• 5 days for uncomplicated influenza in otherwise healthy patients 1
• Do NOT routinely use higher than FDA-approved doses 1

Extended duration considerations:

• Immunocompromised patients with protracted viral replication
• Hospitalized patients with severe lower respiratory disease (pneumonia, ARDS)
• Consider longer courses when viral replication persists beyond 7-10 days 1

Critical Timing

Initiate treatment as soon as possible—ideally within 48 hours of symptom onset 1, 4, 3. However, for hospitalized patients and those with severe illness, start antivirals regardless of how long symptoms have been present 1. Early treatment reduces illness duration by 1-2 days, decreases complications, and can prevent 1,215-14,184 hospitalizations annually in the US 5, 4. The greatest impact occurs in adults ≥65 years and high-risk individuals 5.

Managing Treatment Failure

If patients fail to improve after 3-5 days or deteriorate:

1. Investigate and empirically treat bacterial coinfection (Streptococcus pneumoniae, Staphylococcus aureus) 1

   • Particularly critical in patients with extensive pneumonia, respiratory failure, hypotension, or fever
   • Essential for those who initially improve then worsen

2. Consider NAI resistance testing for:

   • Patients developing influenza while on/after chemoprophylaxis
   • Immunocompromised patients with persistent viral replication after 7-10 days
   • Severe influenza not improving with standard treatment 1

3. Investigate alternative diagnoses beyond influenza 1

What NOT to Do

Avoid these common pitfalls:

• Do NOT combine neuraminidase inhibitors 1
• Do NOT use higher than standard FDA-approved doses routinely 1
• Do NOT use corticosteroids for severe influenza (conditional recommendation against) 3
• Do NOT routinely prescribe antibiotics for non-severe influenza without evidence of bacterial coinfection (strong recommendation against) 3
• Do NOT use macrolides, mTOR inhibitors, NSAIDs, or passive immune therapy as adjunctive treatments 3

Special Populations

Pregnant women: Treat with oseltamivir immediately—benefits far outweigh theoretical risks 1

Immunocompromised patients: Consider extended treatment duration due to protracted viral replication; monitor for resistance 1

Children under 2 years: Mandatory treatment regardless of severity 1

Prophylaxis Considerations

While this question focuses on treatment, WHO conditionally recommends prophylaxis with oseltamivir, zanamivir, baloxavir, or laninamivir for anyone exposed to zoonotic influenza, and for extremely high-risk individuals exposed to seasonal influenza 3.